Benson Hill Transitions to Licensing Model, Improves Financial Profile in First Quarter
Reported revenues for the quarter were approximately $21.1 million, excluding results of the divested processing assets, as the business transitions to an asset-light... Read more.
Bruker Corporation to Host Investor Webinar on May 17, 2024
BILLERICA, Mass.–(BUSINESS WIRE)–$BRKR #BRKR—Bruker Corporation (Nasdaq: BRKR) today announced it intends to hold an Investor Webinar from 10 am... Read more.
LENSAR Reports First Quarter 2024 Results and Provides Business Update
Total Revenue increased 28% and Procedure volume increased 25% over the first quarter of 2023 Increased ALLY® Adaptive Cataract Treatment System installed base... Read more.
Abridge and UChicago Medicine to Collaborate on Research Using AI-Generated Clinical Conversation Data
PITTSBURGH–(BUSINESS WIRE)–Today, Abridge announced that the University of Chicago Medicine will make Abridge’s generative AI platform for clinical... Read more.
Shift4 Announces First Quarter 2024 Results
CENTER VALLEY, Pa.–(BUSINESS WIRE)–$FOUR–Shift4 (NYSE: FOUR), the leader in integrated payments and commerce technology, has posted its first quarter... Read more.
AECOM joint venture to provide environmental planning services for the U.S. Navy
DALLAS–(BUSINESS WIRE)–AECOM (NYSE: ACM), the world’s trusted infrastructure consulting firm, today announced that its joint venture with Stantec was... Read more.
Constellation Reports First Quarter 2024 Results
Earnings Release Highlights GAAP Net Income of $2.78 per share and Adjusted (non-GAAP) Operating Earnings of $1.82 per share for the first quarter of 2024 Affirming... Read more.
Solo Brands Announces First Quarter Results
Reaffirms Full Year 2024 Guidance GRAPEVINE, Texas–(BUSINESS WIRE)–Solo Brands, Inc. (NYSE: DTC) (“Solo Brands” or “the Company”) today announced... Read more.
US Foods Reports First Quarter Fiscal Year 2024 Earnings
Grew Net Sales 4.8% to $8.9 Billion and Gross Profit 4.9% to $1.5 Billion Net Income of $82 Million Grew Adjusted EBITDA 6% to $356 Million and Reaffirms Fiscal... Read more.
Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With Curative Intent
RAHWAY, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the Phase... Read more.